AR089691A1 - Derivados heterociclicos - Google Patents
Derivados heterociclicosInfo
- Publication number
- AR089691A1 AR089691A1 ARP130100073A ARP130100073A AR089691A1 AR 089691 A1 AR089691 A1 AR 089691A1 AR P130100073 A ARP130100073 A AR P130100073A AR P130100073 A ARP130100073 A AR P130100073A AR 089691 A1 AR089691 A1 AR 089691A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- disorders
- hydrogen
- optionally substituted
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a compuestos de la fórmula (1) en la que: R¹ es un grupo heteroarilo de uno o dos miembros, elegido entre el grupo de fórmulas (2); R² es hidrógeno o halógeno; o R¹ y R² junto con el átomo de carbono, al que están unidos, pueden formar los anillos del grupo de fórmulas (3); R³ es hidrógeno, halógeno o alquilo inferior; n es el número 1 ó 2; R⁴ es fenilo opcionalmente sustituido por uno o dos sustituyentes elegidos entre halógeno o ciano, o es piridinilo opcionalmente sustituido por halógeno, o es tetrahidropirano, o es -NH-C(O)-fenilo opcionalmente sustituido por halógeno; R⁵ es hidrógeno o halógeno; R⁶ - R¹³ son fenilo opcionalmente sustituido por halógeno; R¹⁴ es -NH-C(O)-fenilo sustituido por halógeno; R¹⁵ es hidrógeno, alquilo inferior sustituido por halógeno o es halógeno; R¹⁶ es hidrógeno o alcoxi inferior; R¹⁷ es piridinilo opcionalmente sustituido por alcoxi inferior o alquilo inferior sustituido por halógeno; o a sales de adición de ácido farmacéuticamente aceptables de los mismos, a todas las mezclas racémicas, a todos sus enantiómeros y/o isómeros ópticos correspondientes y a todas las formas tautómeras de los compuestos de la fórmula (1). Los compuestos de la fórmula (1) tienen buena afinidad con los receptores asociados a las aminas traza (TAAR), en especial con el TAAR1. Estos compuestos pueden utilizarse para el tratamiento de la depresión, los trastornos de ansiedad, el trastorno bipolar, el trastorno de hiperactividad con déficit de atención (ADHD), los trastornos relacionados con el estrés, los trastornos psicóticos, la esquizofrenia, las enfermedades neurológicas, la enfermedad de Parkinson, los trastornos neurodegenerativos, la enfermedad de Alzheimer, la epilepsia, la migraña, la hipertensión, el abuso de sustancias, los trastornos metabólicos, los trastornos de ingestión de comida, la diabetes, las complicaciones diabéticas, la obesidad, la dislipidemia, los trastornos de consumo y asimilación de energía, los trastornos y malfunción de la homeostasis de la temperatura corporal, los trastornos del sueño y del ritmo circadiano y los trastornos cardiovasculares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12150876 | 2012-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089691A1 true AR089691A1 (es) | 2014-09-10 |
Family
ID=47603607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100073A AR089691A1 (es) | 2012-01-12 | 2013-01-09 | Derivados heterociclicos |
Country Status (14)
Country | Link |
---|---|
US (1) | US9181230B2 (es) |
EP (1) | EP2802578B1 (es) |
JP (1) | JP5872069B2 (es) |
KR (1) | KR101631003B1 (es) |
CN (1) | CN104024250B (es) |
AR (1) | AR089691A1 (es) |
BR (1) | BR112014015832A8 (es) |
CA (1) | CA2856204A1 (es) |
ES (1) | ES2554843T3 (es) |
HK (1) | HK1196357A1 (es) |
MX (1) | MX354815B (es) |
RU (1) | RU2621050C2 (es) |
TW (1) | TW201332998A (es) |
WO (1) | WO2013104591A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
JP2015131783A (ja) * | 2014-01-14 | 2015-07-23 | 株式会社日本ファインケム | アリール−1,2,4−トリアゾール誘導体の製造方法 |
JP2019514960A (ja) * | 2016-05-04 | 2019-06-06 | パーデュー ファーマ エルピー | オキサゾリンシュードダイマー、医薬組成物及びその使用 |
KR102161787B1 (ko) * | 2018-07-02 | 2020-10-06 | 한국기초과학지원연구원 | 수면 장애의 예방 또는 치료용 약학적 조성물 |
WO2023033681A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) |
WO2023033679A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | (azacycloalkyl)methoxy-substituted benzamides as modulators of trace amine-associated receptor 1 (taar1) |
WO2023033680A1 (en) | 2021-09-01 | 2023-03-09 | Limited Liability Company «Excellena Research And Development» (Llc «Excellena») | Substituted 2,3,4,5-tetrahydrobenzo[ f][1,4]oxazepines as modulators of trace amine-associated receptor 1 (taar1) |
CN114426494B (zh) * | 2022-01-13 | 2023-09-15 | 江苏海洋大学 | 一种具有作用于taar激动剂的取代甲胺类衍生物 |
CN115785019A (zh) * | 2022-12-07 | 2023-03-14 | 西安都创医药科技有限公司 | 一种乙基-1-氧-4-氮杂螺环[5.5]十一烷-9-羧酸乙酯的合成方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
KR100754596B1 (ko) * | 2001-09-21 | 2007-09-05 | 미쯔비시 웰 파마 가부시키가이샤 | 3-치환-4-피리미돈 유도체 |
AR064660A1 (es) * | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
JP5341084B2 (ja) * | 2007-08-03 | 2013-11-13 | エフ.ホフマン−ラ ロシュ アーゲー | Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
US8288383B2 (en) | 2007-09-14 | 2012-10-16 | Sanofi | 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
-
2013
- 2013-01-08 ES ES13700984.1T patent/ES2554843T3/es active Active
- 2013-01-08 US US14/328,398 patent/US9181230B2/en not_active Expired - Fee Related
- 2013-01-08 WO PCT/EP2013/050170 patent/WO2013104591A1/en active Application Filing
- 2013-01-08 EP EP13700984.1A patent/EP2802578B1/en not_active Not-in-force
- 2013-01-08 CN CN201380004649.4A patent/CN104024250B/zh not_active Expired - Fee Related
- 2013-01-08 JP JP2014551584A patent/JP5872069B2/ja not_active Expired - Fee Related
- 2013-01-08 RU RU2014132044A patent/RU2621050C2/ru not_active IP Right Cessation
- 2013-01-08 CA CA2856204A patent/CA2856204A1/en not_active Abandoned
- 2013-01-08 KR KR1020147022360A patent/KR101631003B1/ko active IP Right Grant
- 2013-01-08 BR BR112014015832A patent/BR112014015832A8/pt not_active Application Discontinuation
- 2013-01-08 MX MX2014008402A patent/MX354815B/es active IP Right Grant
- 2013-01-09 AR ARP130100073A patent/AR089691A1/es unknown
- 2013-01-11 TW TW102101212A patent/TW201332998A/zh unknown
-
2014
- 2014-09-29 HK HK14109757.8A patent/HK1196357A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20140116920A (ko) | 2014-10-06 |
EP2802578A1 (en) | 2014-11-19 |
US9181230B2 (en) | 2015-11-10 |
BR112014015832A2 (pt) | 2017-06-13 |
CN104024250B (zh) | 2016-01-27 |
KR101631003B1 (ko) | 2016-06-15 |
JP2015503600A (ja) | 2015-02-02 |
WO2013104591A1 (en) | 2013-07-18 |
JP5872069B2 (ja) | 2016-03-01 |
MX2014008402A (es) | 2014-08-22 |
BR112014015832A8 (pt) | 2017-07-04 |
RU2621050C2 (ru) | 2017-05-31 |
ES2554843T3 (es) | 2015-12-23 |
EP2802578B1 (en) | 2015-10-07 |
CA2856204A1 (en) | 2013-07-18 |
TW201332998A (zh) | 2013-08-16 |
RU2014132044A (ru) | 2016-03-10 |
HK1196357A1 (zh) | 2014-12-12 |
US20150045359A1 (en) | 2015-02-12 |
MX354815B (es) | 2018-03-22 |
CN104024250A (zh) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089691A1 (es) | Derivados heterociclicos | |
AR088741A1 (es) | Derivados de pirazol | |
ECSP13012896A (es) | Derivados heterocíclicos de amina | |
ECSP12012098A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
CO6321133A2 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns | |
MY176030A (en) | Substituted benzamide derivatives | |
AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
UY31632A1 (es) | Piridinil amidas para el tratamiento de trastornos del snc y metabólicos | |
ECSP11010782A (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
MX2017001096A (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
AR086880A1 (es) | Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central | |
MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
AR100210A1 (es) | Derivados de piridina con afinidad a taar | |
MX2015001108A (es) | Derivados de triazol carboxamida. | |
AR092537A1 (es) | Derivados de pirazol-carboxamida | |
AR093372A1 (es) | Derivados de pirazina | |
AR059182A1 (es) | Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos | |
AR101339A1 (es) | Derivados del 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o del 3-aminocroman-7-ilo | |
BR112013010558A2 (pt) | derivados de di-hidro-oxazol-2-amina | |
MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
AR063811A1 (es) | 4-imidazoles sustituidos | |
AR067675A1 (es) | 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc. | |
MX2016016190A (es) | Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |